SignalXSignalX

FOLD AMICUS THERAPEUTICS, INC.

8-K Current Report
Filed: March 3, 2026
Health Care
Pharmaceutical Preparations
AMICUS THERAPEUTICS, INC. Overview

AMICUS THERAPEUTICS, INC. (FOLD) 8-K current report filed with SEC EDGAR on March 3, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

  • Item 5.07: Submission of Matters to a Vote of Security Holders

AI Filing Analysis
8-K

Item 5.07 · Submission of Matters to a Vote of Security Holders

  • • Stockholder approval secured: 234.6M shares (99.9% of votes cast) approved BioMarin acquisition of Amicus, clearing key merger condition
  • • FTC early termination granted Feb 11, 2026 — U.S. antitrust clearance already obtained
+2 more insights

Get deeper insights on AMICUS THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.